Melanie A. Nix Provides Advice for a New Cancer Advocate

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

A phase 1 trial of camizestrant with ribociclib appears safe and effective in patients with ER+/HER2- advanced breast cancer.

“This benefit in local recurrence translates into a later difference in distant recurrence and breast cancer [mortality], but it’s only apparent with long follow-up,” according to the study author.